ICC rejects Pakistan’s Rs 447-cr compensation claim against India on bilateral cricket

Mount Maunganui, Feb 12: India captain Virat Kohli on Tuesday berated his bowlers for their mediocre performance as he tried to explain the team's first ODI series whitewash in over three decades, saying that the visitors lacked composure all through.

The five-wicket defeat here meant that India lost the series 0-3 to an injury-plagued New Zealand that had been deflated by a 0-5 whitewash of its own in the T20 format just last week. It was India's first whitewash in 31 years in an ODI series in which all matches have been played.

"The games were not as bad as the scoreline suggests. It boils down to those chances that we didn't grab. I don't think it was not enough to win games in international cricket," Kohli said in the post-match presentation.

"With the ball, we were not able to make breakthroughs, we were not at all good on the field. We haven't played so badly but when you don't grab those chances, you don't deserve to win," he added.

"Batsmen coming back from tough situations was a positive sign for us, but the way we fielded and bowled, the composure wasn't enough to win games," he asserted.

The ineffectiveness of Indian bowlers can be gauged from the fact that the team's pace spearhead Jasprit Bumrah finished the series without a wicket and the attack couldn't dismiss the complete rival line-up even once.

Kohli lauded New Zealand for bouncing back after the T20 hammering.

"New Zealand played with lot more intensity. We didn't deserve to win because we did not show enough composure," he said.

The batting mainstay is looking forward to the Test series, which begins on February 21, to make amends for the disappointment.

"I think because of the Test Championship, every match has that more importance. We have a really balanced Test team and we feel we can win the series here, but we need to step on to the park with the right kind of mindset," he said.

His opposite number Kane Williamson, who missed the first two games due to injury, was lavish in his praise for the home team's grit.

"An outstanding performance, very clinical. India put us under pressure, but the way the guys fought back with the ball and kept them to a par total. The cricket in the second half was outstanding to see," he said referring to the side's effortless chase of a 297-run target.

"We know how good they (India) are at all formats but for us the clarity about the roles the guys had was the most important thing. Outstanding effort against a brilliant India side," he added.

Player of the Match Henry Nicholls, who scored 80 on Tuesday, said his team benefitted from good batting starts during the series.

"To come back and win 3-0 after the T20Is is nice. The way (Martin) Guptill played today allowed us to get ahead. We got a 100-run stand, but we were fortunate enough to get good starts this series," he said.

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.

Colombo, Jul 5: Sri Lanka batsman Kusal Mendis was on Sunday arrested for knocking down a pedestrian while driving, police said.

Mendis hit a 74-year-old man, killing him in the wee hours, in the Colombo suburb of Panadura.

He is to be produced before a magistrate later today, police said.

The 25-year-old wicket-keeper batsman has represented Sri Lanka in 44 Tests and 76 ODIs. Mendis was part of the national squad which had resumed training after the Covid-19 lockdown.

Sri Lanka's international assignments, including a tour by India, have been cancelled due to the pandemic.